OncoSec Medical Inc (ONCSQ)

[Waitforit53]

What I like about the heat collaboration is the expanded number of indications OncoSec has in the pipeline.
GOTTA KNOW WHAT YOU OWN HERE!
1) Melanoma initiated 1Q - Merck

2) Squamous Cell Carcinoma of the Head and Neck (SCCHN) initiated 1Q
Dr. Mai H. Le, Chief Medical Officer at OncoSec, stated, “Similar to melanoma, recent data suggest that in SCCHN, tumor-infiltrating lymphocytes [TILs] are required to achieve responses to anti-PD-1 drugs such as pembrolizumab. We believe that as a single agent, IL-12 ImmunoPulse has the potential to convert tumors from a low to a high-TIL state.”

Heat Biologic is presently in P2 with the follow indications:
3)Lung
AND
4) Bladder 80% and 75% patients respectively, do not respond to Heat Biologics "Impact" drug.

Article Head line of ZACKS from three month ago needs to be updated from

"ONCS: Results from Newly Initiated Phase II Combination Trial Could Lead to a Big License Deal"

to

"ONCS: Results from Multiple, Newly Initiated Trials in Melanoma, SCCHN, Lung, and Bladder Could Lead to Multiple Big Licensing Deals"

This 1st Quarter's success in increasing the immunogenicity of cancerous tumors is a make-or-break moment in OncoSec moment in immunotherapy history. I realize they have a fledgling drug development program, but drugs are slow movers through the FDA approval program. The next three to six months must yield, with a degree of consistency across all the above mentioned indications, the power to Make responders out of Non-responders.

So What's at stake for ONCS PPS: I think that if ImmunoPulse performs as expected, the PPS should determined by "billions" in revenue not millions. It helps if you Stop thinking like a trader and start thinking like an institutional investor--then you know the data about the TIL's is yet to come. IT'S ALL ABOUT THE TIL's! Which means for right now, its all about waiting for Trials.